Cargando…

β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib

INTRODUCTION: The overexpression of human epidermal growth factor receptor (HER)-2 in 20% of human breast cancers and its association with aggressive growth has led to widespread use of HER2-targeted therapies, such as trastuzumab (T) and lapatinib (L). Despite the success of these drugs, their effi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Catherine, Park, Catherine C, Hilsenbeck, Susan G, Ward, Robin, Rimawi, Mothaffar F, Wang, Yen-chao, Shou, Jiang, Bissell, Mina J, Osborne, C Kent, Schiff, Rachel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3236347/ https://www.ncbi.nlm.nih.gov/pubmed/21884573 http://dx.doi.org/10.1186/bcr2936

Ejemplares similares

Different mechanisms for resistance to trastuzumab versus lapatinib in HER2- positive breast cancers -- role of estrogen receptor and HER2 reactivation
por: Wang, Yen-Chao, et al.
Publicado: (2011)

The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance
por: Nardone, Agostina, et al.
Publicado: (2018)

Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models
por: Veeraraghavan, Jamunarani, et al.
Publicado: (2021)

Endocrinology and hormone therapy in breast cancer: New insight into estrogen receptor-α function and its implication for endocrine therapy resistance in breast cancer
por: Schiff, Rachel, et al.
Publicado: (2005)

Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis
por: Giuliano, Mario, et al.
Publicado: (2015)

t-Darpp overexpression in HER2-positive breast cancer confers a survival advantage in lapatinib
por: Christenson, Jessica L., et al.
Publicado: (2015)

Circulating tumor cell investigation in breast cancer patient-derived xenograft models by automated immunofluorescence staining, image acquisition, and single cell retrieval and analysis
por: Ramirez, Arturo B., et al.
Publicado: (2019)

Pertuzumab, Trastuzumab, and an Aromatase Inhibitor for HER2-Positive and Hormone Receptor–Positive Metastatic or Locally Advanced Breast Cancer: PERTAIN Final Analysis
por: Arpino, Grazia, et al.
Publicado: (2023)

Role of lapatinib in the first-line treatment of patients with metastatic breast cancer
por: Oakman, Catherine, et al.
Publicado: (2010)

β1 and β4 integrins: from breast development to clinical practice
por: Nisticò, Paola, et al.
Publicado: (2014)

Lapatinib-induced acute generalized exanthematous pustulosis
por: Lakshmi, Chembolli, et al.
Publicado: (2010)

Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase
por: Fu, Xiaoyong, et al.
Publicado: (2014)

Breast adenocarcinoma recurring as small cell carcinoma in a patient with a germline BRCA2 mutation: clonal evolution unchecked
por: Niravath, Polly, et al.
Publicado: (2015)

A CTC-Cluster-Specific Signature Derived from OMICS Analysis of Patient-Derived Xenograft Tumors Predicts Outcomes in Basal-Like Breast Cancer
por: Thangavel, Hariprasad, et al.
Publicado: (2019)

A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer
por: Cristofanilli, Massimo, et al.
Publicado: (2012)

Efficacy and Tolerability of Lapatinib in the Management of Breast Cancer
por: Rana, Punam, et al.
Publicado: (2012)

Targeted treatment of advanced and metastaticbreast cancer with lapatinib
por: Corkery, Brendan, et al.
Publicado: (2008)

Development of the Rat Model of Lapatinib-Induced Diarrhoea
por: Bowen, Joanne M.
Publicado: (2014)

The concomitant use of lapatinib and paracetamol - the risk of interaction
por: Karbownik, Agnieszka, et al.
Publicado: (2018)

MYC Suppresses Cancer Metastasis by Direct Transcriptional Silencing of αv and β3 Integrin Subunits
por: Liu, Hong, et al.
Publicado: (2012)

Combining lapatinib and pertuzumab to overcome lapatinib resistance due to NRG1-mediated signalling in HER2-amplified breast cancer
por: Leung, Wing-yin, et al.
Publicado: (2015)

Lumpectomy followed by radiation improves survival in HER2 positive and triple‐negative breast cancer with high tumor‐infiltrating lymphocytes compared to mastectomy alone
por: Mouabbi, Jason A., et al.
Publicado: (2021)

The HER2 inhibitor lapatinib potentiates doxorubicin-induced cardiotoxicity through iNOS signaling
por: Hsu, Wan-Tseng, et al.
Publicado: (2018)

Lapatinib, Nilotinib and Lomitapide Inhibit Haemozoin Formation in Malaria Parasites
por: de Sousa, Ana Carolina C., et al.
Publicado: (2020)

Synergistic Antitumor Effects on Drug-Resistant Breast Cancer of Paclitaxel/Lapatinib Composite Nanocrystals
por: Wang, Jun, et al.
Publicado: (2020)

Metastatic squamous cell carcinoma of the skin with clinical response to lapatinib
por: Strickley, John D., et al.
Publicado: (2018)

Synergistic Activity of the HSP90 Inhibitor Ganetespib With Lapatinib Reverses Acquired Lapatinib Resistance in HER2-Positive Breast Cancer Cells
por: Ye, Min, et al.
Publicado: (2021)

Lapatinib Induces Autophagy, Apoptosis and Megakaryocytic Differentiation in Chronic Myelogenous Leukemia K562 Cells
por: Huang, Huey-Lan, et al.
Publicado: (2011)

Dose-reduced trastuzumab deruxtecan can be safely used in liver failure and active leptomeningeal metastases
por: Higashiyama, Nicole, et al.
Publicado: (2020)

Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer
por: Creighton, Chad J, et al.
Publicado: (2010)

Lapatinib for the treatment of breast cancer in the People’s Republic of China
por: Wang, Hongjiang
Publicado: (2014)

Therapeutic Mechanism of Lapatinib Combined with Sulforaphane on Gastric Cancer
por: Yi, Huixing, et al.
Publicado: (2021)

Evaluation of Lapatinib-Loaded Microfibers Prepared by Centrifugal Spinning
por: Bitay, Enikő, et al.
Publicado: (2022)

Different chemical proteomic approaches to identify the targets of lapatinib
por: Kovačević, Tatjana, et al.
Publicado: (2023)

HBx sensitizes hepatocellular carcinoma cells to lapatinib by up-regulating ErbB3
por: Chen, Jhen-Yu, et al.
Publicado: (2015)

Cytotoxic effect of lapatinib is restricted to human papillomavirus-positive head and neck squamous cell carcinoma cell lines
por: Fumagalli, Ingrid, et al.
Publicado: (2015)

Alternative Mechanisms for Talin to Mediate Integrin Function
por: Klapholz, Benjamin, et al.
Publicado: (2015)

Adipocyte-conditioned medium induces resistance of breast cancer cells to lapatinib
por: Geneste, A., et al.
Publicado: (2020)

BCAR4 induces antioestrogen resistance but sensitises breast cancer to lapatinib
por: Godinho, M F E, et al.
Publicado: (2012)

Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases – the UK experience
por: Sutherland, S, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_1ldkpg79kkcm3egbbpekq83213